Laurent Humeau Net Worth

The estimated Net Worth of Laurent Humeau is at least $2.18 Milión dollars as of 15 May 2024. Laurent Humeau owns over 4,771 units of Inovio Pharmaceuticals Inc stock worth over $170,562 and over the last 6 years he sold INO stock worth over $1,034,984. In addition, he makes $972,531 as Chief Scientific Officer at Inovio Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Laurent Humeau INO stock SEC Form 4 insiders trading

Laurent has made over 19 trades of the Inovio Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,771 units of INO stock worth $31,250 on 15 May 2024.

The largest trade he's ever made was exercising 68,811 units of Inovio Pharmaceuticals Inc stock on 26 February 2023 worth over $450,712. On average, Laurent trades about 25,545 units every 82 days since 2019. As of 15 May 2024 he still owns at least 26,040 units of Inovio Pharmaceuticals Inc stock.

You can see the complete history of Laurent Humeau stock trades at the bottom of the page.

Laurent Humeau biography

Dr. Laurent M. Humeau Ph.D. serves as Chief Scientific Officer of the Company. Dr. Humeau has served as our Chief Scientific Officer since March 2019, having previously served as our Vice President and then Senior Vice President of Research and Development beginning in January 2014. Prior to joining us, Dr. Humeau was Senior Director of Translational Research, Human Therapeutics Division for Intrexon Corporation and previously served in a variety of roles, including Chief Scientific Officer and Vice President of Research and Development, at VIRxSYS Corporation. Dr. Humeau holds a Ph.D., summa cum laude, from Denis Diderot University (Paris 7) and a M.S. degree in Biology from Pierre & Marie Curie University (Paris 6).

What is the salary of Laurent Humeau?

As the Chief Scientific Officer of Inovio Pharmaceuticals Inc, the total compensation of Laurent Humeau at Inovio Pharmaceuticals Inc is $972,531. There are 4 executives at Inovio Pharmaceuticals Inc getting paid more, with Jong Kim having the highest compensation of $2,588,530.

How old is Laurent Humeau?

Laurent Humeau is 53, he's been the Chief Scientific Officer of Inovio Pharmaceuticals Inc since 2018. There are 11 older and 3 younger executives at Inovio Pharmaceuticals Inc. The oldest executive at Inovio Pharmaceuticals Inc is Simon Benito, 75, who is the Independent Chairman of the Board.

What's Laurent Humeau's mailing address?

Laurent's mailing address filed with the SEC is C/O INOVIO PHARMACEUTICALS, INC., 6769 MESA RIDGE RD., SAN DIEGO, CA, 92121.

Insiders trading at Inovio Pharmaceuticals Inc

Over the last 20 years, insiders at Inovio Pharmaceuticals Inc have traded over $23,656,819 worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth $5,174,071 . The most active insiders traders include Austin W & Greenhouse David..., Jong Joseph Kim a Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $745,390. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth $19,106.

What does Inovio Pharmaceuticals Inc do?

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Complete history of Laurent Humeau stock trades at Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc executives and stock owners

Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jong Kim,
  President, Chief Executive Officer, Director
• Dr. J. Joseph Kim,
  CEO, Pres & Director
• Jacqueline Elizabeth Shea,
  Chief Operating Officer
• Peter Kies,
  Chief Financial Officer
• Laurent Humeau,
  Chief Scientific Officer
• Peter D. Kies,
  Chief Financial Officer
• Dr. Laurent M. Humeau,
  Chief Scientific Officer
• Dr. Jacqueline E. Shea Ph.D.,
  Chief Operating Officer
• David Weiner,
  Director
• Lota Zoth,
  Independent Director
• Simon Benito,
  Independent Chairman of the Board
• Ann Miller,
  Independent Director
• Wendy Yarno,
  Independent Director
• Jay Shepard,
  Independent Director
• Asli Gevgilili,
  Chief HR Officer
• Robert L. Crotty J.D.,
  Gen. Counsel
• Robert J. Juba Jr.,
  Sr. VP of Biological Manufacturing & Clinical Supply Management
• Dr. Jeffrey Skolnik,
  Sr. VP of Clinical Devel.
• Dr. Ami Shah Brown,
  Sr. VP of Regulatory Affairs
• Jessica C. Lee MS, MPH,
  Sr. VP of Clinical Operations & Global Integration
• E. J. Brandreth,
  Sr. VP of Quality Assurance
• Ben Matone,
  Director of Investor Relations
• Morton Collins,
  Director
• George Bickerstaff,
  Director
• Adel Mahmoud,
  Director
• Mark Bagarazzi,
  Chief Medical Officer
• Niranjan Sardesai,
  Sr. VP Research & Development
• Nancy Wysenski,
  Director
• Avtar S Dhillon,
  President & CEO
• Angel Cabrera,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Dietmar P Rabussay,
  V.P. Research & Development
• George F. Iii Mc Hugh,
  Vice President, Operations
• Eugene A Larson,
  Director
• Felix Theeuwes,
  Director
• Robert S Goodenew,
  V.P. Corporate Development
• Michael Fons,
  VP, Corporate Development
• Kevin Rassas,
  Sr. VP Business Development
• Cheryl Jo White,
  Chief Medical Officer
• Tee Khiang Ng,
  Director
• Robert William Rieder,
  Director
• James L Heppell,
  Director
• David J Williams,
  Director
• Punit Dhillon,
  VP, Finance & Operations
• Riaz Amirali Bandali,
  Director
• Stephen Rietiker,
  Director
• Beng Lee Gan,
  Director
• Tazdin Esmail,
  Director
• Keith H Wells,
  Director
• Chin Cheong Chong,
  Director
• Roger D Dansey,
  Director
• Michael John Sumner,
  Chief Medical Officer